INSIGHTS ON DRUG DEVELOPMENT

• Column Selection For RPLC-UV Impurity Analysis

  Explore the performance of four column chemistries for RPLC-UV impurity analysis of liraglutide and semaglutide, which offers practical guidance for method development in peptide-based therapeutics.

• Nose To Brain (N2B) Drug Delivery – Benefits And Challenges

  Delve into the growing interest in drug delivery methods that target the brain and central nervous system via absorption into the bloodstream, specifically focusing on crossing the blood-brain barrier (BBB).

• Overcoming Excipient Risks And Challenges For Parenteral Formulations

  Excipients are essential to parenteral formulations, which help protect APIs, enhance stability, and ensure safety. Learn how strategic excipient selection can optimize drug performance and patient outcomes.

• Solving The Inhalation Puzzle: A CDMO's Guide To Dry Powder Development

  Gain guidance on the choice of formulation, excipients, and the micronization technologies offered by CDMOs, and learn about current encapsulation technologies for inhaled products.

• Target Product Profile (TPP) Explained

  7/27/2026

  Learn how to best align your development strategy, guide cross-functional decisions, and build a clear pathway from discovery to successful commercialization.

• A Comparison To Traditional Clone Screening Platforms

  8/6/2026

  See how 46 CHO clones performed across automated, deep-well, and microbioreactor fed-batch cultures, using cell density, viability, and IgG concentration to evaluate clone performance.

• The Patent Cliff Looms – Design Your Biosimilar Approach Accordingly

  3/3/2025

  In your pursuit of developing a high-quality biosimilar, think strategically. Consider what type of biologic your team’s expertise can support and which is needed most in your target market.

• Lipid Formulations In Softgels: Enhancing Bioavailability And Therapeutic Efficacy

  8/31/2026

  Discover how lipid-based softgel formulations can enhance drug absorption, improve bioavailability, and advance drug delivery across a range of therapeutic applications.

• Ushering In A New Era Of Human-Relevant Drug Discovery

  7/29/2026

  With most drug candidates failing before approval, researchers need better ways to predict human responses. Gain insight into how advances in human-relevant modeling are helping improve decisions.